OS Therapies Q2 EPS Reduced by Brookline Capital Markets

OS Therapies Incorporated (NYSEAMERICAN:OSTX) – Stock analysts at Brookline Capital Markets dropped their Q2 2026 earnings estimates for shares of OS Therapies in a research note issued on Monday, June 8th. Brookline Capital Markets analyst K. Raja now anticipates that the company will earn ($0.23) per share for the quarter, down from their prior forecast of ($0.19). The consensus estimate for OS Therapies’ current full-year earnings is $0.16 per share. Brookline Capital Markets also issued estimates for OS Therapies’ Q3 2026 earnings at ($0.19) EPS, Q4 2026 earnings at ($0.18) EPS, FY2026 earnings at ($0.84) EPS, FY2027 earnings at ($0.29) EPS, FY2028 earnings at ($0.16) EPS, FY2029 earnings at $0.09 EPS and FY2030 earnings at $0.15 EPS.

OS Therapies (NYSEAMERICAN:OSTX) last released its earnings results on Monday, May 18th. The company reported ($0.27) EPS for the quarter.

OSTX has been the topic of several other research reports. Lake Street Capital cut their price objective on OS Therapies from $14.00 to $13.00 and set a “buy” rating on the stock in a research report on Tuesday, May 19th. D. Boral Capital restated a “buy” rating and issued a $20.00 price target on shares of OS Therapies in a report on Thursday, April 30th. Finally, Zacks Research raised shares of OS Therapies from a “strong sell” rating to a “hold” rating in a research note on Thursday, June 4th. Two research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $16.50.

OS Therapies Stock Performance

Shares of OSTX stock opened at $1.74 on Wednesday. The stock has a 50 day moving average price of $1.62 and a 200 day moving average price of $1.55. OS Therapies has a 52-week low of $1.15 and a 52-week high of $2.57. The firm has a market capitalization of $77.50 million, a P/E ratio of -1.61 and a beta of -0.95.

Institutional Investors Weigh In On OS Therapies

Several hedge funds have recently made changes to their positions in the company. Susquehanna International Group LLP purchased a new position in shares of OS Therapies during the third quarter valued at $29,000. Jane Street Group LLC bought a new stake in shares of OS Therapies in the fourth quarter valued at about $39,000. XTX Topco Ltd purchased a new stake in OS Therapies in the second quarter worth about $63,000. Virtu Financial LLC grew its holdings in OS Therapies by 252.0% during the 3rd quarter. Virtu Financial LLC now owns 75,801 shares of the company’s stock worth $149,000 after acquiring an additional 54,269 shares in the last quarter. Finally, Two Sigma Investments LP bought a new position in OS Therapies during the 3rd quarter worth about $169,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.